CollabRx Partners With Sengenics for Molecular Diagnostics

CollabRx Partners With Sengenics for Molecular Diagnostics

SAN FRANCISCO, April 9, 2013 (GLOBE NEWSWIRE) -- CollabRx, Inc. (Nasdaq:CLRX),
today announced a partnership with Sengenics, a leading genetic diagnostics
company, to provide turn-key diagnostic decision making solutions for Asian
and global markets. Sengenics plans to incorporate CollabRx's interpretive
content resources into its molecular cancer diagnostics tests and reports.

"Sengenics has become a widely recognized pioneer in this field, as it was the
first company outside the US to offer genomics-based research and diagnostic
services," said CollabRx Chairman, President and Chief Executive Officer
Thomas Mika. "We look forward to partnering with Sengenics on a powerful joint
offering in clinical cancer sequencing."

Sengenics plans to offer cancer exome sequencing tests combined with CollabRx
interpretive analytics to create a comprehensive medical informatics solution.
The solution is being designed to seamlessly pair tests results with
clinically actionable and dynamically updated knowledge on the clinical impact
of specific tumor genetic profiles and associated therapeutic strategies such
as drugs and clinical trials. CollabRx will provide the content in a
SaaS-based business model.

"We are excited about partnering with CollabRx and developing such an
important turn-key solution for clinical cancer sequencing," said Dr. Anwar,
Executive Director of Sengenics. "Our joint solution's ability to provide
insights from CollabRx's clinical practitioner network represents critical and
timely value to physicians when they are interpreting test results."

The partnership leverages CollabRx's semantic integration platform, a
scalable, proprietary technology that enables CollabRx scientists and
physicians to dynamically update the company's molecular oncology knowledge
base with the latest medical and scientific data available in the public

The partnership, leveraging on Sengenics' status as a prominent commercial
entity in the genomics and diagnostics space, extends CollabRx's business to
three continents: North America, Europe and Asia.

"CollabRx has established an industry standard for interpretive reporting in
cancer diagnostics which this agreement helps to expand globally," said Mr.
Mika. "We also look forward to working with Sengenics to expand our
interpretive content to genomic disease areas outside of cancer."

Sengenics has a portfolio of more than 400 genetic tests for Development
Delay, Rare Genetic Disorders, Cardiac risk, Thalassaemia and Cancer.

About CollabRx

CollabRx, Inc. (Nasdaq:CLRX) is a recognized leader in cloud-based expert
systems to inform healthcare decision-making. CollabRx uses information
technology to aggregate and contextualize the world's knowledge on
genomics-based medicine with specific insights from the nation's top cancer
experts, starting with the area of greatest need: advanced cancers in patients
who have effectively exhausted the standard of care. More information may be
obtained at

About Sengenics

Sengenics was the 1st company outside the USA to offer genomics-based
diagnostics services. The key focus areas for the company are Diagnostics and
Research Services using next-generation sequencing, protein and DNA microarray
technologies. The business model of the company also leverages the translation
of joint research projects into patented and commercialized diagnostics tests.
Sengenics has established a wide network of partners in the US, Europe and
Asia as channels for its products and services. The company has sales offices
and genetic testing facilities in four countries. More information may be
obtained at

CollabRx Safe Harbor Statement

This press release includes forward-looking statements about CollabRx's
anticipated results that involve risks and uncertainties. Some of the
information contained in this press release, including, but not limited to,
statements as to industry trends and CollabRx's plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by CollabRx with the Securities and Exchange Commission.
CollabRx undertakes no obligation to update or revise any such forward-looking
statements to reflect subsequent events or circumstances.

CONTACT: CollabRx Contacts:
         Thomas R. Mika, CEO
         CollabRx, Inc.
         Robert Ferri Partners, LLC
         Robert Ferri
         (415) 575-1589 (direct)
         Sengenics Contacts
         Buzzlair Voufincci

CollabRx, Inc. Logo
Press spacebar to pause and continue. Press esc to stop.